RxSight's Strong Q1 Performance and Market Expansion Justify Buy Rating
RxSight Analyst Ratings
Wells Fargo: Maintaining the RxSight (RXST.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $61.00 to $68.00.
Oppenheimer Adjusts RxSight Price Target to $72 From $61, Maintains Outperform Rating
Oppenheimer Remains a Buy on RxSight (RXST)
RxSight Outperforms With Strong Q1 Results and Raised Guidance: Buy Rating Affirmed
BTIG: Maintains RxSight (RXST.US) rating, adjusted from buy to buy rating, and adjusted target price from $61.00 to $72.00.
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)
Stifel: Maintaining the RxSight (RXST.US) rating, adjusted from buy to buy rating, and adjusted the target price from $64.00 to $68.00.
RxSight Analyst Ratings
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and BioMarin Pharmaceutical (BMRN)
Needham: Reiterated the RxSight (RXST.US) rating, adjusted from buy to buy rating, target price $64.00.
RxSight Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)
Patrick Wood Reaffirms Buy Rating for RxSight Amid Strong Growth and Market Expansion Potential
RxSight Analyst Ratings
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating
Oppenheimer Reaffirms Their Buy Rating on RxSight (RXST)
Buy Rating on RxSight: Strong Financials and Positive 2024 Outlook Drive Upward Price Target
Analysts Are Bullish on Top Healthcare Stocks: RxSight (RXST), Personalis (PSNL)